Literature DB >> 21112041

Immunophenotyping in multiple myeloma and related plasma cell disorders.

Shaji Kumar1, Teresa Kimlinger, William Morice.   

Abstract

Plasma cell disorders form a spectrum ranging from the asymptomatic presence of small monoclonal populations of plasma cells to conditions like plasma cell leukemia and multiple myeloma, in which the bone marrow can be replaced by the accumulation of neoplastic plasma cells. Immunophenotyping has become an invaluable tool in the management of hematological malignancies and is increasingly finding a role in the diagnosis and monitoring of plasma cell disorders. Multiparameter flow cytometry has evolved considerably during the past decade with an increasing ability to screen large numbers of events and to detect multiple antigens at the same time. This, along with a better understanding of the phenotypic heterogeneity of the clonal plasma cells in different disorders, has made immunophenotyping an indispensible tool in the diagnosis, prognostic classification and management of plasma cell disorders. This book chapter addresses the approaches taken to evaluate monoclonal plasma cell disorders, and the different markers and techniques that are important for the study of these diseases.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21112041      PMCID: PMC3005703          DOI: 10.1016/j.beha.2010.09.002

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  96 in total

1.  CD200 is a new prognostic factor in multiple myeloma.

Authors:  Jerome Moreaux; Dirk Hose; Thierry Reme; Eric Jourdan; Michael Hundemer; Eric Legouffe; Philippe Moine; Philippe Bourin; Marion Moos; Jill Corre; Thomas Möhler; John De Vos; Jean Francois Rossi; Hartmut Goldschmidt; Bernard Klein
Journal:  Blood       Date:  2006-08-31       Impact factor: 22.113

2.  Quantitation of plasma cells in bone marrow aspirates by flow cytometric analysis compared with morphologic assessment.

Authors:  Kristi J Smock; Sherrie L Perkins; David W Bahler
Journal:  Arch Pathol Lab Med       Date:  2007-06       Impact factor: 5.534

3.  Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders.

Authors:  W G Morice; C A Hanson; S Kumar; L A Frederick; C E Lesnick; P R Greipp
Journal:  Leukemia       Date:  2007-04-26       Impact factor: 11.528

Review 4.  Plasma cell development: from B-cell subsets to long-term survival niches.

Authors:  Kirsten A Fairfax; Axel Kallies; Stephen L Nutt; David M Tarlinton
Journal:  Semin Immunol       Date:  2008-01-28       Impact factor: 11.130

5.  CD28-mediated regulation of multiple myeloma cell proliferation and survival.

Authors:  Nizar J Bahlis; Anne M King; Despina Kolonias; Louise M Carlson; Hong Yu Liu; Mohamad A Hussein; Howard R Terebelo; Gerald E Byrne; Bruce L Levine; Lawrence H Boise; Kelvin P Lee
Journal:  Blood       Date:  2007-02-20       Impact factor: 22.113

6.  CD117 (c-kit) is aberrantly expressed in a subset of MGUS and multiple myeloma with unexpectedly good prognosis.

Authors:  Régis Bataille; Catherine Pellat-Deceunynck; Nelly Robillard; Hervé Avet-Loiseau; Jean-Luc Harousseau; Philippe Moreau
Journal:  Leuk Res       Date:  2007-09-04       Impact factor: 3.156

7.  New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.

Authors:  Ernesto Pérez-Persona; María-Belén Vidriales; Gema Mateo; Ramón García-Sanz; Maria-Victoria Mateos; Alfonso García de Coca; Josefina Galende; Guillermo Martín-Nuñez; José M Alonso; Natalia de Las Heras; José M Hernández; Alejandro Martín; Consuelo López-Berges; Alberto Orfao; Jesús F San Miguel
Journal:  Blood       Date:  2007-06-18       Impact factor: 22.113

8.  Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14).

Authors:  M Hundemer; U Klein; D Hose; M-S Raab; F W Cremer; A Jauch; A Benner; C Heiss; M Moos; A D Ho; H Goldschmidt
Journal:  Bone Marrow Transplant       Date:  2007-09-24       Impact factor: 5.483

9.  Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma.

Authors:  Maria Kraj; Urszula Sokołowska; Joanna Kopeć-Szlezak; Ryszard Pogłód; Barbara Kruk; Jolanta Woźniak; Tomasz Szpila
Journal:  Leuk Lymphoma       Date:  2008-02

10.  Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.

Authors:  Andy C Rawstron; Alberto Orfao; Meral Beksac; Ludmila Bezdickova; Rik A Brooimans; Horia Bumbea; Klara Dalva; Gwenny Fuhler; Jan Gratama; Dirk Hose; Lucie Kovarova; Michael Lioznov; Gema Mateo; Ricardo Morilla; Anne K Mylin; Paola Omedé; Catherine Pellat-Deceunynck; Martin Perez Andres; Maria Petrucci; Marina Ruggeri; Grzegorz Rymkiewicz; Alexander Schmitz; Martin Schreder; Carine Seynaeve; Martin Spacek; Ruth M de Tute; Els Van Valckenborgh; Nicky Weston-Bell; Roger G Owen; Jesús F San Miguel; Pieter Sonneveld; Hans E Johnsen
Journal:  Haematologica       Date:  2008-02-11       Impact factor: 9.941

View more
  38 in total

1.  Reduction in plasma cell proliferation after initial therapy in newly diagnosed multiple myeloma measures treatment response and predicts improved survival.

Authors:  Jeremy T Larsen; Cheng E Chee; John A Lust; Philip R Greipp; S Vincent Rajkumar
Journal:  Blood       Date:  2011-07-12       Impact factor: 22.113

2.  CD138 Negative Plasma Cells in Relapsed CNS Multiple Myeloma.

Authors:  Neha Singh; Jatin S Gandhi; Narendra Agrawal; Ajit Panaych; Narender Tejwani; Anurag Mehta
Journal:  Indian J Hematol Blood Transfus       Date:  2017-02-07       Impact factor: 0.900

Review 3.  Clinical Relevance of Multicolour Flow Cytometry in Plasma Cell Disorders.

Authors:  Gaurav Chatterjee; Sumeet Gujral; Papagudi G Subramanian; Prashant R Tembhare
Journal:  Indian J Hematol Blood Transfus       Date:  2017-04-26       Impact factor: 0.900

4.  Monitoring of Measurable Residual Disease in Multiple Myeloma by Multiparametric Flow Cytometry.

Authors:  Kah Teong Soh; Paul K Wallace
Journal:  Curr Protoc Cytom       Date:  2019-07-17

5.  Antigen-mediated regulation in monoclonal gammopathies and myeloma.

Authors:  Shiny Nair; Joel Sng; Chandra Sekhar Boddupalli; Anja Seckinger; Marta Chesi; Mariateresa Fulciniti; Lin Zhang; Navin Rauniyar; Michael Lopez; Natalia Neparidze; Terri Parker; Nikhil C Munshi; Rachael Sexton; Bart Barlogie; Robert Orlowski; Leif Bergsagel; Dirk Hose; Richard A Flavell; Pramod K Mistry; Eric Meffre; Madhav V Dhodapkar
Journal:  JCI Insight       Date:  2018-04-19

6.  Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma.

Authors:  Alberto L Horenstein; Valeria Quarona; Denise Toscani; Federica Costa; Antonella Chillemi; Vito Pistoia; Nicola Giuliani; Fabio Malavasi
Journal:  Mol Med       Date:  2016-10-13       Impact factor: 6.354

7.  Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.

Authors:  Shaji Kumar; Angela Dispenzieri; Martha Q Lacy; Suzanne R Hayman; Francis K Buadi; Colin Colby; Kristina Laumann; Steve R Zeldenrust; Nelson Leung; David Dingli; Philip R Greipp; John A Lust; Stephen J Russell; Robert A Kyle; S Vincent Rajkumar; Morie A Gertz
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

8.  A phase 1 trial of 90Y-Zevalin radioimmunotherapy with autologous stem cell transplant for multiple myeloma.

Authors:  A Dispenzieri; A D'Souza; M A Gertz; K Laumann; G Wiseman; M Q Lacy; B LaPlant; F Buadi; S R Hayman; S K Kumar; D Dingli; W J Hogan; S M Ansell; D A Gastineau; D J Inwards; I N Micallef; L F Porrata; P B Johnston; M R Litzow; T E Witzig
Journal:  Bone Marrow Transplant       Date:  2017-09-04       Impact factor: 5.483

9.  Isolation of circulating plasma cells from blood of patients diagnosed with clonal plasma cell disorders using cell selection microfluidics.

Authors:  Joyce W Kamande; Maria A M Lindell; Małgorzata A Witek; Peter M Voorhees; Steven A Soper
Journal:  Integr Biol (Camb)       Date:  2018-02-19       Impact factor: 2.192

10.  Neoplastic plasma cell aberrant antigen expression patterns and their association with genetic abnormalities.

Authors:  Mohamed E Salama; Shouying Du; Olga Efimova; Nahla M Heikal; Erik Wendlandt; Reha M Toydemir; Sarah South; Sherrie L Perkins; Jerry W Hussong; Fenghuang Zhan
Journal:  Leuk Lymphoma       Date:  2014-08-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.